NEW YORK, June 14, 2012 \/PRNewswire\/ -- The second installment of the successful EBM Debates series, launched in March 2012, will go live tomorrow, Friday, June 15, beginning at 12:30 PM Pacific, 2:30 PM Central, and 3:30 PM Eastern. This debate will cover a topic of increasing importance in the field of Alzheimer's disease research: \"Why are there so many late-stage drug development failures in Alzheimer's disease?\" Powered 4 Significance LLC, a Blue Ocean Pharma company, is hosting the virtual event that will have faculty joining from two locations Houston and Las Vegas. <\/p>\n
(Logo: http:\/\/photos.prnewswire.com\/prnh\/20120125\/NY41522LOGO<\/a>) <\/p>\n We are excited to present our internationally recognized faculty for this debate, including the moderator and host, Marwan Sabbagh, MD, FAAN, and panelists Jeffrey Cummings, MD, ScD, Director of the Cleveland Clinic Lou Ruvo Center for Brain Health, Rachelle S. Doody, MD, PhD, Director of the Alzheimer's Disease and Memory Disorders Center, Baylor College of Medicine Department of Neurology, and Martin Farlow, MD, Associate Co-Director of the Indiana Alzheimer's Disease Center. <\/p>\n Panelists will discuss the topic at hand and answer questions submitted by the registered audience prior to and during the live debate. \"Our goal is to shed light on why the research community and pharmaceutical companies are not experiencing more success in the development of Alzheimer's treatments,\" said Alden E. Masonis, PhD, co-founding partner of Powered 4 Significance and Blue Ocean Pharma. <\/p>\n Virtual participants are able to register for the event and submit questions through the EBM Debates website (www.ebmdebates.com). The debate will be archived and available for playback after the event. <\/p>\n Evidence-Based Medicine Debates (EBM Debates)The EBM Debates series has been created by Powered 4 Significance (www.powered4significance.com) based on an identified need for an open dialog among physicians involved in disease research and management, for a better understanding of important and controversial issues in disease diagnosis and treatment. The goal is to bring together researchers, thought leaders, and treating physicians to gain insight into the evidence base and enable informed decision-making. For more information on the EBM Debates, please visit http:\/\/www.ebmdebates.com<\/a>. <\/p>\n Blue Ocean Pharma LLCBlue Ocean is on the forefront of developments in the pharmaceutical and healthcare sectors. Our services span the clinical development and commercialization needs of our clients and focus on supporting pharmaceutical, biotechnology, and device development, giving healthcare professionals the opportunity to optimize patient care and improve outcomes. <\/p>\n The Blue Ocean Pharma Group of companies consists of Percolation Communications LLC, i.e. Strategy LLC, and Powered 4 Significance LLC. Together, the Group offers complementary and unique services that provide synergistic support addressing client needs. To learn more about Blue Ocean Pharma, please visit us at http:\/\/www.blueoceanpharma.com<\/a>. <\/p>\n Blue Ocean Pharma Contact: Marco Winkler +1 917 376 3019 mwinkler@blueoceanpharma.com<\/a> <\/p>\n<\/p>\n More:<\/p>\n Evidence-Based Medicine Debate Series Tackles The Issue of Late-Stage Drug Development Failures In Alzheimer's Disease<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" NEW YORK, June 14, 2012 \/PRNewswire\/ -- The second installment of the successful EBM Debates series, launched in March 2012, will go live tomorrow, Friday, June 15, beginning at 12:30 PM Pacific, 2:30 PM Central, and 3:30 PM Eastern. This debate will cover a topic of increasing importance in the field of Alzheimer's disease research: \"Why are there so many late-stage drug development failures in Alzheimer's disease?\" Powered 4 Significance LLC, a Blue Ocean Pharma company, is hosting the virtual event that will have faculty joining from two locations Houston and Las Vegas Continue reading